TC-510 for Mesothelioma
This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
- Pancreatic Cancer
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Bile Duct Cancer
- Pancreatic Adenocarcinoma
- Ovarian Tumors
- Non-Small Cell Lung Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many participants are eligible to partake in the experiment?
"Affirmative. Clinicaltrials.gov reveals that this experiment has been actively recruiting volunteers since June 21st 2022, with the most recent update occuring on September 21st 2022. The trial is looking for 115 subjects at 2 distinct medical facilities."
Is the enrollment process for this trial currently open?
"This clinical trial is currently enrolling participants, as indicated on its page hosted by clinicaltrials.gov. It was initially published on June 21st 2022 and has been amended most recently on September 21st 2022."